Brigham and Women's Hospital-Harvard Medical School Pulmonary and Critical Care Fellowship Faculty: Ivan O. Rosas, M.D.
Ivan O. Rosas, M.D.
Assistant Professor of Medicine, Harvard Medical School


Dr. Rosas’ main clinical research interest is to determine the natural history of early stages of pulmonary fibrosis in susceptible cohorts.  Through extensive phenotyping of patients affected with sporadic Idiopathic Pulmonary Fibrosis (IPF), kindred’s affected with Familial Pulmonary Fibrosis (FPF), and rheumatoid arthritis patients affected with secondary pulmonary fibrosis his research has shown that early pulmonary fibrosis can be readily detected in populations at risk. More recently his research has focused on the incidence of early interstitial lung disease in smokers.

Dr. Rosas’ translational research efforts have focused on identifying novel molecular targets for diagnosis and treatment of human pulmonary fibrosis. Using gene-expression micro-arrays and targeted proteomics of broncho-alveolar lavage and peripheral blood his research group has identified increases in levels of Syndecan-2 and Matrix Metalloprotease -7 in the lungs and peripheral blood of patients affected with IPF suggesting that these proteins may have a role in disease progression. Presently his bench research focuses on potential molecular mechanisms by which these proteins contribute to the development of human pulmonary fibrosis.

Dr. Rosas is a member of the Brigham and Women's Hospital Interstitial Lung Disease Program and the Brigham and Women's Hospital Lung Transplant Program. The Brigham and Women's Hospital Interstitial Lung Disease Program provides multi-disciplinary outpatient and inpatient care to patients affected with diverse forms of pulmonary fibrosis. Patients undergo an extensive evaluation by a pulmonologist, rheumatologist, cardiologist and if required a thoracic surgeon. Once diagnosis is confirmed patients are treated with standard of care approaches and are invited to participate in clinical research trials or translational research protocols.


  1. Kaminski N, Rosas IO.  Gene expression profiling as a window into IPF pathogenesis: Can we identify the right target genes? Proc Am Thorac Soc 2006; 3:339-344.

  2. Rosas, IO, Kaminski N.  When it comes to genes - IPF or NSIP, Familial or Sporadicthey're all the same. Am J Respir Crit Care Med 2007; 175(1):5-6.

  3. Ren P, Rosas IO, MacDonald SD, Wu HP, Billings EM, Gochuico BR.  Impairment of alveolar macrophage transcription in idiopathic pulmonary fibrosis.   Am J Respir Crit Care Med 2007; 175:1151-1157.

  4. Rosas IO, Ren P, Avila NA, Choi K, Terry, F, William TD, McCoy JP, May RM, Nguyen DM, Wu HP, MacDonald SD, Gochuico BR.  Early interstitial lung disease in familial pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176:698-705.

  5. Gochuico BR, Avila NA, Novero LJ, Stylianou MP, Travis WD, Parker CY, Wu HP, Ren P, MacDonald SD, Rosas IO.  Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008; 168(2):159-166.

  6. Rosas IO, Richards TJ, Kazuhisha K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, MacDonald SD, Pardo A, Sciurba F, Dauber J, Selman M, Gochuico BR, Kaminski N. MMP1 and MMP7 as potential blood biomarkers in idiopathic pulmonary fibrosis. PLoS Medicine, 2008 Apr 29;5(4):e93.

  7. Kliment CR, Englert JM, Gochuico BR, Yu G, Kaminski N, Rosas I, Oury TD. Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis. J Biol Chem. 2009; 284(6):3537-3545.

  8. El-Chemaly S, Malide D, Sudaire E, Ikeda Y, Weinberg BA, Pacheco-Rodriguez G, Rosas IO, Aparicio M, Ren P, MacDonald SD, Wu HP, Nathan SD, Cuttitta F, McCoy JP, Gochuico BR, Moss J.  Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms.  Proc Natl Acad Sci USA 2009; 106(10):3958-3963. (PMID 19237567)

  9. Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, Fertig N, Oddis CV, Kaminski N, Rosas IO, Ascherman DP.  Characterization and peripheral blood biomarker assessment of Jo-1 antibody-positive insterstitial lung disease.  Arthritis Rheum 2009; 60(7):2183-92. (PMID: 19565490)

  10. Washko GR, Lynch DA, Matsuoka S, Ross J, Umeoka S, Scuirba F, Hunninghake GM, Sciurba F, Silverman EK, Rosas IO, Hatabu H.  Identification of early interstitial lung disease in smokers from the COPDGene study.  Acad Radiol 2010; 17(1):48-53. (PMID 1978163).